You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CDX-301

Showing 1 - 25 of 254
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pancreatic Cancer, Cancer of the Pancreas, Pancreas Cancer Trial in Saint Louis (CDX-301, CDX-1140, Research blood draw)

Recruiting
  • Pancreatic Cancer
  • +2 more
  • CDX-301
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 17, 2023

Melanoma, Metastatic Melanoma Trial in Boston (CDX-301, NEOVAX, Nivolumab)

Recruiting
  • Melanoma
  • Metastatic Melanoma
  • CDX-301
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Jan 12, 2023

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8 Trial in Los

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +5 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +3 more
  • Los Angeles, California
    USC/Norris Comprehensive Cancer Center
Jan 31, 2023

Non Small Cell Lung Cancer, Lung Cancer Trial in Bronx (drug, biological, radiation)

Recruiting
  • Non Small Cell Lung Cancer
  • Lung Cancer
  • FLT3 Ligand (CDX-301)
  • +2 more
  • Bronx, New York
    Albert Einstein College of Medicine
Jul 18, 2022

Metastatic Triple Negative Breast Cancer Trial in Dallas (PLD Chemotherapy, CDX-1140, CDX-301)

Recruiting
  • Metastatic Triple Negative Breast Cancer
  • PLD Chemotherapy
  • +2 more
  • Dallas, Texas
    UT Southwestern Medical Center
Jun 23, 2022

Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary Trial in United States (DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly

Completed
Has Results
  • Cutaneous Melanoma
  • +11 more
  • DEC-205/NY-ESO-1 Fusion Protein CDX-1401
  • +2 more
  • Chicago, Illinois
  • +6 more
Nov 10, 2021

Prostate Cancer Trial in New York (PGV-001, Poly-ICLC, CDX-301)

Recruiting
  • Prostate Cancer
  • PGV-001
  • +2 more
  • New York, New York
    Icahn School of Medicine at Mount Sinai (ISMMS)
Aug 10, 2021

Melanoma, NSCLC, Breast Cancer Trial in United States (CDX-1140, CDX-301, Pembrolizumab)

Completed
  • Melanoma
  • +25 more
  • Scottsdale, Arizona
  • +10 more
Sep 27, 2022

NSCLC (NSCLC) Trial in Bronx (FLT3 Ligand Therapy (CDX-301), Stereotactic Body Radiotherapy (SBRT))

Active, not recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • FLT3 Ligand Therapy (CDX-301)
  • Stereotactic Body Radiotherapy (SBRT)
  • Bronx, New York
    Montefiore Medical Center
Nov 5, 2021

Breast Cancer Trial in United States (radiation, drug, biological)

Recruiting
  • Breast Cancer
  • Focal Radiation therapy
  • +2 more
  • Los Angeles, California
  • +6 more
Apr 29, 2022

Metastatic Castration-resistant Prostate Cancer Trial in United States (drug, radiation, device)

Completed
  • Metastatic Castration-resistant Prostate Cancer
  • NKTR-214 (Cohort A)
  • +6 more
  • Los Angeles, California
  • +5 more
Nov 10, 2022

Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma Trial in New York (Pembrolizumab, Flt3L,

Recruiting
  • Non-Hodgkin's Lymphoma
  • +2 more
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Oct 18, 2021

Low-Grade B-cell Lymphoma Trial in New York (rhuFlt3L/CDX-301, Poly-ICLC)

Recruiting
  • Low-Grade B-cell Lymphoma
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Nov 17, 2020

Exocrine Pancreatic Insufficiency Trial in Adelaide, Auckland, Christchurch (Part A, Part B, Part C)

Recruiting
  • Exocrine Pancreatic Insufficiency
  • Part A
  • +2 more
  • Adelaide, New South Wales, Australia
  • +3 more
Jan 12, 2023

Melanoma Trial in United States (glembatumumab vedotin, glembatumumab vedotin and varlilumab, glembatumumab vedotin and PD-1

Terminated
Has Results
  • Melanoma
  • glembatumumab vedotin
  • +3 more
  • Los Angeles, California
  • +13 more
Sep 5, 2019

Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases Trial in Miami, Morgantown (linsitinib)

Recruiting
  • Thyroid Eye Disease
  • +11 more
  • Miami, Florida
  • +1 more
Oct 31, 2023

Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in

Not yet recruiting
  • Ovarian Clear Cell Adenocarcinoma
  • +14 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +4 more
  • Buffalo, New York
  • +1 more
Dec 16, 2022

Chronic Spontaneous Urticaria Trial in Germany, United States (CDX-0159, Normal Saline)

Completed
  • Chronic Spontaneous Urticaria
  • Birmingham, Alabama
  • +13 more
Jan 24, 2023

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Active, not recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +5 more
  • Tucson, Arizona
  • +16 more
Oct 19, 2022

Cold Urticaria, Cold Contact Urticaria, Symptomatic Dermographism Trial in Berlin (CDX-0159)

Active, not recruiting
  • Cold Urticaria
  • +4 more
  • Berlin, Germany
    Charite University
Dec 20, 2022

Prurigo Nodularis Trial in Germany, United States (CDX-0159, Normal saline)

Recruiting
  • Prurigo Nodularis
  • CDX-0159
  • Normal saline
  • Tempe, Arizona
  • +18 more
Jan 4, 2023

Systemic Lupus Erythematosus (SLE) Trial (BRL-301)

Not yet recruiting
  • Systemic Lupus Erythematosus (SLE)
  • BRL-301
  • (no location specified)
Aug 13, 2023

Glioma Trial (Blood sampling)

Not yet recruiting
  • Glioma
  • Blood sampling
  • (no location specified)
Oct 31, 2023

Cocaine Use Disorder, Substance Use Disorders, Healthy Volunteers Trial in Overland Park (TMP-301, Placebo)

Active, not recruiting
  • Cocaine Use Disorder
  • +2 more
  • Overland Park, Kansas
    Altasciences
Aug 29, 2023

Chronic Spontaneous Urticaria Trial in Hungary, United States (barzolvolimab, Matching Placebo)

Recruiting
  • Chronic Spontaneous Urticaria
  • barzolvolimab
  • Matching Placebo
  • Birmingham, Alabama
  • +44 more
Dec 8, 2022